Regulatory milestones

Biogen Idec Inc. (NASDAQ:BIIB) gained $0.49 to $144.28 last week, while partner Elan Corp. plc (NYSE:ELN) was off $0.34 to $10 after FDA and EMA accepted for review regulatory applications to expand the label of Tysabri natalizumab to include first-line treatment for relapsing forms of multiple sclerosis in anti-JC virus (JCV) antibody-negative patients. The PDUFA date is not disclosed.